1- Melmed S, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth facto-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicentre study with a 52 week open extension. Pituitary 2010; 13: 18-28.
2- Colao A, et al. Pasireotide vs. Octreotide in Acromegaly: A Head-to-Head Superiority Study. J Clin Endocrinol Metab 2014; 99(3):791-799.
PP-RDP-GBR-0311. January 2020.